[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053914":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":34,"collaborators":10,"id":36,"slug":10,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":10,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Physicians group",null,"Physicians who have experience in the treatment and management of stage IV NSCLC patients with 1L EGFR-TKI.",{"label":13,"type":10,"description":14,"interventionNames":10},"Patinet group","Patients receiving or who have received 1L EGFR-TKI treatment for stage IV NSCLC",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[22],{"facility":23,"status":24,"city":25,"state":10,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":10},"Research Site","RECRUITING","Chengdu","610000","China",{"type":29,"coordinates":30},"Point",[31,32],104.06667,30.66667,{"lat":32,"lon":31},{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100053914",false,"NCT07413757","CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC","A Cross-sectional Survey-based Study Using Preference Elicitation Method to Assess Decision-making Impact Factor of Chinese Patients and Physicians for First-line EGFR-TKIs Treatment of Stage IV NSCLC (CHOICE)","CHOICE","Inclusion Criteria:\n\nThe following inclusion criteria must be met in order to be enrolled in the stage 1:\n\nPatient:\n\n* Provide informed consent\n* 18 years or older\n* Diagnosed with stage IV NSCLC\n* Currently receiving or previously received 1L EGFR-TKI treatment\n* Without communication barrier\n* Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter\n\nPhysician:\n\n* Provide informed consent\n* Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals\n* Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month\n* Holding the title of associate chief physician or higher\n\nThe following inclusion criteria must be met in order to be enrolled in the stage 2:\n\nPatient:\n\n* Provide informed consent\n* 18 years or older\n* Diagnosed with stage IV NSCLC\n* Currently receiving or previously received 1L EGFR-TKI treatment\n* Without communication barrier\n* Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter\n\nPhysician:\n\n* Provide informed consent\n* Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals\n* Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month\n* Holding the title of attending physician or higher\n\nExclusion Criteria:\n\nNot applicable.","ALL","18 Years",{"count":46,"type":47},590,"ESTIMATED","OBSERVATIONAL","This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.",[51],"Non-Small Cell Lung Cancer",[53],"NSCLC;patients and physicians;survey;EGFR-TKI;patient preference;physician preference","2026-07-10",{"date":56,"type":57},"2026-07-13","ACTUAL",{"date":59,"type":57},"2026-03-02",{"date":61,"type":47},"2026-07-31",{"name":5,"class":6},1]